Trial reportJournal of traumatic stress2026
Cognition improvement in U.S. veterans undergoing treatment for posttraumatic stress disorder: Secondary analyses from a randomized controlled trial.
Trial report in Journal of traumatic stress, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cognitive dysfunction is a hallmark of posttraumatic stress disorder (PTSD). Although treatments effectively reduce core PTSD symptoms, limited research has examined whether associated cognitive impairments improve following treatment. This study investigated cognitive changes in veterans receiving treatment for PTSD and explored the associations between cognitive improvement and PTSD symptom reduction. U.S. veterans (N = 85) with clinically significant PTSD symptoms were randomized to receive either cognitive processing therapy (CPT; n = 44) or Sudarshan Kriya yoga (SKY; n = 41) in a noninferiority trial. Cognitive function was assessed pre- and posttreatment using the Cambridge Neuropsychological Test Automated Battery. PTSD symptoms were assessed using the Clinician-Administered PTSD Scale (CAPS-5). Following treatment, participants showed significant improvements in episodic visual memory, d = 0.51, p < .001; motor learning, d = 0.57, p < .001; and visual sustained attention, d = 0.37, p = .005. There were no significant differences in cognitive improvement between the CPT and SKY groups. Changes in overall cognitive function were significantly correlated with PTSD symptom reductions across both treatment groups. Regardless of treatment, cognitive function improved alongside PTSD symptom reduction. These findings provide evidence that treating PTSD not only alleviates PTSD symptoms but may also improve associated cognitive function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.